{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Gastric+Adenocarcinoma&page=2", "query": { "condition": "Locally Advanced Gastric Adenocarcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Gastric+Adenocarcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T09:17:21.386Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Junction", "Gastroesophageal Adenocarcinoma", "Esophageal Neoplasms", "Esophageal Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab Tirumotecan (sac-TMT)", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Patritumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2024-09-20", "completion_date": "2029-09-12", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06469944" }, { "nct_id": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "ramucirumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tucatinib placebo", "type": "OTHER" }, { "name": "trastuzumab placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-22", "completion_date": "2024-04-17", "has_results": true, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04499924" }, { "nct_id": "NCT00062374", "title": "Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Stage II Gastric Cancer", "Stage III Gastric Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Fluorothymidine F-18", "type": "OTHER" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2003-06", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062374" }, { "nct_id": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer", "Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer", "Head and Neck Cancer", "Differentiated Thyroid Cancer", "Lower Esophageal Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2017-09-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170960" }, { "nct_id": "NCT04879368", "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-Oesophageal Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Trifluridine/Tipracil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Australasian Gastro-Intestinal Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 462, "start_date": "2021-05-05", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Edgewood", "state": "Kentucky" }, { "city": "Rapid City", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879368" }, { "nct_id": "NCT00021047", "title": "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Portsmouth, Virginia", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Portsmouth", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021047" }, { "nct_id": "NCT07182149", "title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HNSCC", "ESCC", "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Ovarian Cancer", "NSCLC", "Cervical Cancer", "Endometrial Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "NRM-823", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Normunity AccelCo, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-10-30", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 9, "location_summary": "Denver, Colorado • New Haven, Connecticut • Minneapolis, Minnesota + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Maumee", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07182149" }, { "nct_id": "NCT00183911", "title": "Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastric Cancer" ], "interventions": [ { "name": "floxuridine, 5-Fluorouracil, leucovorin", "type": "DRUG" }, { "name": "External Beam Radiotherapy", "type": "PROCEDURE" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2003-11", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00183911" }, { "nct_id": "NCT07594548", "title": "Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Esophageal Adenocarcinoma", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Futibatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2027-09-09", "completion_date": "2031-09-09", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 2, "location_summary": "Chicago, Illinois • Columbus, Ohio", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07594548" }, { "nct_id": "NCT06901531", "title": "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer", "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer", "Metastatic Gastric Adenocarcinoma or Cancer", "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Folinic acid (leucovorin or local equivalent)", "type": "DRUG" }, { "name": "5-fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2025-05-22", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-11T09:17:21.386Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Bakersfield, California • Cerritos, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06901531" } ] }